Stifel analyst Benjamin J. Burnett lowered the price target on bluebird bio (NASDAQ: BLUE) to $18.00 (from $31.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

bluebird bio (BLUE) PT Lowered to $19 at Morgan StanleyAugust 11, 2021 8:26 AM Goldman Sachs Downgrades bluebird bio (BLUE) to NeutralAugust 10, 2021 6:56 AM SVB Leerink Downgrades bluebird bio (BLUE) to Market Perform, Following Earnings, Business UpdateAugust 9, 2021 12:45 PM bluebird bio (BLUE) Misses Q2 EPS by 39cAugust 9, 2021 7:12 AM Form 10-Q bluebird bio, Inc. For: Jun 30August 9, 2021 7:05 AM Form 8-K bluebird bio, Inc. For: Aug 09August 9, 2021 7:03 AM bluebird bio Reports Second Quarter Financial Results and Provides Operational UpdateAugust 9, 2021 7:00 AM bluebird bio Announces Q2 Earnings Call and Upcoming Investor EventsAugust 5, 2021 4:05 PM